Business
Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range
First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to
About this update from Cerus Corporation
[{"type":"text","content":"\nFirst Half of 2024 Product Revenue Increased 20% from Prior Year Period\n\n\nIncreasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million\n\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024.\n\n\nTotal revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %):\n\n\n\n\n\nThree Months Ended\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nSix Months Ended\n\n\n\n\n\n\n\n\n\n\n\n\n\nJune 30,\n\n\n\n\n\n\n\nChange\n\n\n\n\n\n\n\nJune 30,\n\n\n\n\n\n\n\nChange\n\n\n\n\n\n\n\n\n\n2024\n\n\n\n\n\n\n\n2023\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n2024\n\n\n\n\n\n\n\n2023\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nProduct Revenue\n\n\n\n\n\n\n$\n\n\n\n\n\n\n45,079\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n38,853\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n6,226\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n16\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n83,444\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n69,827\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n13,617\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n20\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nGovernment Contract Revenue\n\n\n\n\n\n\n \n\n\n\n\n\n\n5,440\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n8,875\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n(3,435\n\n\n\n\n\n\n)\n\n\n\n\n\n\n\n-39\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n10,470\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n16,377\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n(5,907\n\n\n\n\n\n\n)\n\n\n\n\n\n\n\n-36\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nTotal Revenue\n\n\n\n\n\n\n$\n\n\n\n\n\n\n50,519\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n47,728\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n2,791\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n6\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n93,914\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n86,204\n\n\n\n\n\n\n\n$\n\n\n\n\n\n\n7,710\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n9\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\nRecent highlights include:\n\n\n\nAdvanced efforts to expand the U.S. manufacturing capacity for INTERCEPT Fibrinogen Complex (IFC).\n\n\n\nAchievement of 100% adoption of INTERCEPT platelets by Canadian Blood Services, resulting in the pathogen inactivation of the majority of platelets in Canada.\n\n\n\nNarrowed GAAP net loss attributable to Cerus Corporation to $5.8 million and generated non-GAAP adjusted EBITDA of $0.8 million for the second quarter.\n\n\n\nGenerated positive operating cash flows fo...